美瑞健康国际产业集团
Meilleure Health International Industry Group

MEILLEURE HEALTH INTERNATIONAL INDUSTRY GROUP LIMITED
美瑞健康國際產業集團有限公司

(Incorporated in Bermuda with limited liability)

(Stock Code: 2327)

POSTIVIE PROFIT ALERT

This announcement is made by Meilleure Health International Industry Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09(2)(a) of The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

The board (the "**Board**") of directors (the "**Director(s)**") of the Company would like to inform the shareholders of the Company (the "**Shareholders**") and potential investors of the Company that, based on the preliminary review of the unaudited consolidated management accounts of the Group for the six months ended 30 June 2025 and the information currently available to the Company, the Group expects to record a profit attributable to the Shareholders in the range of approximately HK$14.0 million to HK$16.0 million for the six months ended 30 June 2025 as compared to a profit attributable to the Shareholders of approximately HK$8.2 million for the six months ended 30 June 2024. Such expected increase is mainly due to the following reasons:

(i) an increase in the revenue from and profit of property-related business of the Group as a result of an increase in rental income and no material fair value change in the Group's investment properties expected to be recorded for the six months ended 30 June 2025, as compared to a significant decrease in the fair value of the Group's investment properties for the six months ended 30 June 2024;

(ii) a significant increase in interest income, attributable to the Group's effective utilization of idle funds by providing short-term interest-bearing loans and long-term interest-bearing revolving facility to its customers and a related party,

which are partially offset by the following unfavourable factor:

(iii) a decrease in trade sales and sale of healthcare-related products as the operating environment in the PRC remains challenging.

The information contained in this announcement is only based on a preliminary assessment by the Board according to the unaudited consolidated management accounts of the Group for the six months ended 30 June 2025 and the information available to the Board as at the date of this announcement, which have not been reviewed, confirmed or audited by the Company's auditors and/or the audit committee and are subject to adjustment. The Company is in the process of preparing and finalising the Group's interim results for the six months ended 30 June 2025. Details of the Group's financial information for the six months ended 30 June 2025 will be disclosed in its interim results announcement which is expected to be published on or before 28 August 2025.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company and, in case of doubt, to seek independent advice from professional or financial advisers.

By Order of the Board
Meilleure Health International Industry Group Limited
Zhou Wen Chuan
Executive Director and Chief Executive Officer

Hong Kong, 15 August 2025

As at the date of this announcement, the Board comprises Mr. Zhou Xuzhou, Dr. Zeng Wentao and Ms. Zhou Wen Chuan as executive Directors, Dr. Mao Zhenhua as non-executive Director and Professor Chau Chi Wai, Wilton, Mr. Chen Shi and Mr. Wu Peng as independent non-executive Directors.